We are currently working on

Oxcia is currently engaged in development or commercialization of projects concerning the following targets:


In the end of 2016, the Medical Product Agency (MPA) approved a clinical phase 1 trial, MASTIFF (MTH1, A phase I, Study on Tumors Inhibition, First in human, First in class with EudraCT no: 2016-002624-80), investigating safety and tolerability of Karonudib in cancer patients with advanced solid malignancies. Thomas Helleday Foundation for Medical Research is the sponsor of the MASTIFF trial, but has appointed Oxcia AB to assist in the clinical development and commercialization. During summer 2019 approval for the MAATEO (A phase 1 study in MDS, AML and ALL patients to evaluate safety, tolerability and efficacy of Karonudib with EUDRACT no: 2019-001221-27) was obtained and will be started during the fall.

Many cancers have a dysfunctional redox status and upregulated levels of MTH1, suggesting that MTH1 is necessary for the cancer cell to survive the high load of oxidative stress and oxidized nucleotides. MTH1 (NUDT1) is a sanitizing enzyme, hydrolysing oxidized nucleotides into their monophosphates, thereby hindering them to be incorporated into DNA and cause mutations (Nakabeppu et al., 2010). By knocking down MTH1, cancer cells can no longer survive, while normal cells still divide and live (Gad et al., Nature 2014; Rai et al., 2011, Ling et al., 2016 etc). In Professor Thomas Helleday laboratory at Karolinska Institute, small molecule inhibitors against MTH1 was identified and shown to kill a variety of cancer cells in vitro and reduce tumour growth in mice xenograft disease models (Gad et al., Nature 2014; Warpman Berglund et al., Annals of Oncology 2016).

Oxcia AB has been crucial for patent strategies and clinical development strategies for the MTH1 project. Oxcia AB has, been responsible for planning, preparing, initiating both the clinical trial MASTIFF and MAAETO, and are now managing it according to GCP, GMP, GLP and applicable regulations.


Oxcia is developing OGG1 inhibitors against severe lung diseases in collaboration with Swedish academia, Karolinska Institutet, Lund University, Uppsala University and Stockholm University.

Proof of principle has been demonstrated in mice, showing that therapeutic treatment with our tool compound, an OGG1 inhibitor, TH5487 significantly reduces lung inflammation.

Targeting OGG1 is a completely novel approach for treatment of inflammatory. The pro-inflammatory immune cells that drive auto-immunity and inflammation suffer from high level of oxidative stress and therefore require specific detoxification enzymes for survival and function. One enzyme of specific interest is OGG1, 8oxo guanine glycosylase1. Through binding to promoter regions, enriched in oxidized guanines, this enzyme recruits other proteins such as transcription factors, e.g. NF-Ƙβ to form complexes, promoting transcription of pro-inflammatory genes. Our OGG1 inhibitor TH5487 prevents OGG1 from binding to DNA and thereby dampening the inflammatory responses in animal models (Visnes et al, Science, Nov 16, 2018). http://science.sciencemag.org/content/362/6416/834

Helleday lab at the Karolinska Institute is advancing the lead optimization of OGG1 inhibitors to develop novel therapies for severe lung inflammation diseases with large medical need such as ARDS, COPD, severe non allergic asthma and idiopathic pulmonary fibrosis (IPF).

Oxcia is responsible for the business and market strategies, IPR and regulatory strategies of the project. Oxcia is open for partnership to enable development of potential therapies and launch of novel products.

Oxcia in collaboration with Karolinska Institutet, Lund University and Uppsala University, have been granted 5 Million SEK by Swelife and Vinnova in support of the OGG1 project. Swelife is a strategic innovation programme, funded by the Programme Partners and the Swedish Government via the Swedish innovation agency, Vinnova. Swelife support collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.